English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/154777
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Biological and pharmacological characterization of benzothiazole-based CK-1δ inhibitors in models of Parkinson’s disease

AuthorsMorales-García, José A. ; Salado, Irene G. ; Sanz-SanCristóbal, Marina ; Gil, Carmen ; Pérez Castillo, Ana ; Martínez, Ana ; Pérez, Daniel I.
KeywordsDrug discovery and Drug delivery systems
Heterocyclic compounds
Structure-activity relationship
Issue Date30-Aug-2017
PublisherAmerican Chemical Society
CitationACS Omega 2(8): 5215–5220 (2017)
AbstractParkinson’s disease (PD), an age-related neurodegenerative disorder that results from a progressive loss of dopaminergic neurons has an enormous economical and human cost. Unfortunately, only symptomatic treatment such as dopamine replacement therapy is available. Therefore, drugs with new mechanisms of action able to protect against neuronal cell death are an urgent need. We here report the in vivo efficacy on dopaminergic neuronal protection in a PD mouse model and the lack of toxicity in zebrafish and Ames test of benzothiazole-based casein kinase-1δ (CK-1δ) nanomolar inhibitors. On the basis of these results, we propose protein kinase CK-1δ inhibitors as the possible disease-modifying drugs for PD, benzothiazole 4 being a promising drug candidate for further development as a new therapy of this neurodegenerative disease.
Publisher version (URL)http://dx.doi.org/10.1021/acsomega.7b00869
Appears in Collections:(CIB) Artículos
(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
acsomega.7b00869.pdfArtículo principal5,3 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.